What is semaglutide?
Semaglutide copies GLP-1, the fullness hormone your gut releases after eating — slowing digestion, quieting appetite, and steadying blood sugar. It's one of the most-studied molecules in modern metabolic medicine.
These articles cover it from every angle: mechanism, dosing, side effects, results measured in trials, and how compounded semaglutide differs from brand-name versions. It's prescription-only through Promise: a licensed provider reviews every request, and not everyone qualifies. If you're starting from zero, begin with the mechanism article — the rest makes more sense once the hormone story is clear.
188 articles on this topic
-
Orforglipron Is Approved: What Foundayo Changes
Orforglipron is now sold as Foundayo, a once-daily GLP-1 pill for weight management. It removes the fasting rules of oral semaglutide, but it does not replace every reason someone may choose an injection.
-
Retatrutide Early Access Is Real—and Very Limited
Retatrutide early access now exists through a narrow, doctor-led program. It is not a public prescription route, a sale, or an approval.
-
Semaglutide and Kidney Disease: The Full Picture
In the largest trial on the question, serious kidney events were 24% less common on semaglutide than on placebo. The other half of the story is dehydration — and the two keep getting confused.
-
Compounded Medication Recall: Check the Lot
A recall usually applies to one pharmacy, one preparation and specific lot numbers—not every compounded medication. Here is how to check a vial and reach the people responsible for it.
-
What Is Cagrilintide? The Amylin Half of CagriSema
Cagrilintide is an experimental copy of the appetite hormone amylin, and the other half of Novo Nordisk's CagriSema. It is not approved, it is not sold here, and a US decision is expected before the end of 2026.
-
Semaglutide and Tirzepatide Together? Usually No
Semaglutide and tirzepatide together are not a recommended combination. Both reach the same GLP-1 pathway; a switch should be planned as one treatment replacing the other, with timing and dose set by a prescriber.
-
GLP-1 Heart Failure Guidelines Changed in 2026
Europe's 2026 ESC guideline now says semaglutide or tirzepatide should be considered for a narrow group with symptomatic heart failure and obesity. It is an option for a cardiologist to weigh, not a direction to start either drug on your own.
-
Semaglutide for Children: What STEP Young Means
Semaglutide for children ages 6 to 11 has encouraging new trial results, but the news has not changed who can receive Wegovy under its current label. The evidence is promising, early, and best read with a pediatrician.
-
What Is Semaglutide Used For? A Plain Guide
Semaglutide has different jobs depending on the brand: blood sugar control, heart or kidney risk reduction, long-term weight management, or certain liver disease. Here is the plain list before a first visit.
-
Zepbound vs Wegovy: Two Drugs, Not Two Brands
They get compared like two versions of one medicine. They are not — different molecules, different makers, and different lists of what each one is cleared to treat.
-
No Shortcut: The Peptide FDA Approval Process
Mimrylo’s August 2026 approval is a useful look at the whole path: permission to begin human studies, three trial phases, a full application, manufacturing review, and a label limited to one use.
-
Retatrutide Lawsuit: It Is Still Investigational
Lilly sued six sellers in August, but the practical answer predates the cases: retatrutide remains investigational and no pharmacy can lawfully compound it for patients.
-
Semaglutide and Heart Health: What Studies Show
Semaglutide has been linked to fewer major cardiovascular events in a specific high-risk group, and to better symptoms in one type of heart failure. The numbers are meaningful, but they do not apply to every heart or every formulation.
-
Semaglutide and Vision: What's Real, What's Rare
Most people never have an eye problem because of semaglutide. Two things do come up, though, and they get mixed together constantly — so here is what each one actually is.
-
Semaglutide for Heart Failure Now Has ESC Support
Europe's 2026 heart-failure guideline now says semaglutide or tirzepatide should be considered for symptomatic patients with obesity and an ejection fraction of at least 45%. The recommendation is about symptoms, walking capacity, and quality of life—not proof that semaglutide prevents death.
-
Tirzepatide Diabetic Retinopathy: Who It's For
The tirzepatide diabetic retinopathy warning was revised on both U.S. labels in August 2026. It asks for eye monitoring in people who already have the condition — not a finding that the medicine harms eyes.
-
Tirzepatide vs Ozempic: What You're Comparing
Ozempic is a brand of semaglutide, approved for type 2 diabetes. Tirzepatide is a different molecule with its own brands — so the comparison most people want is between two drugs, not a drug and a label.
-
Compounded Tirzepatide Court Ruling Upholds FDA
The Fifth Circuit left FDA's tirzepatide shortage decision in place. That closes the broad shortage-era compounding route, but it does not erase the narrower rules for an identified patient.
-
GLP-1 Patches: Do They Work?
GLP-1 patches sold online are usually supplement stickers, not semaglutide or tirzepatide. Ordinary patches cannot move these large peptide drugs across intact skin in a predictable dose.
-
Semaglutide and Aging: The New Study Is in Mice
A new Nature study found longer life and better physical function in old female mice given semaglutide. It did not test people, so it cannot tell us that semaglutide slows human aging or adds years to human life.
Page 7 of 10 · 188 articles